Affimed Announces Collaboration With Genentech To Develop Novel NK Cell Engager-based Immunotherapeutics For Multiple Cancer Targets; Co. Will Receive $96M Upfront And Committed Funding, Is Eligible For $5B Including Milestone Payments, Royalties